Vectus Biosystems Limited

Equities

VBS

AU000000VBS9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 08:29:40 2024-05-15 pm EDT			5-day change	1st Jan Change
0.2 ^AUD	-14.89%		-14.89%	-33.33%

Feb. 23	Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
2023	Vectus Biosystems Limited Announces the Change of its Registered Office and Principal Place of Business Address	CI

Vectus Biosystems Limited Announces Successful Completion of First Group in Phase I Human Trial

August 22, 2021 at 07:43 pm EDT

Vectus Biosystems Limited (Vectus or the Company) announced that the first cohort consisting of eight subjects has completed all protocol requirements for the 2mg dose in the Single Ascending Dose (SAD) component of its Phase I/IB trial entitled: The results for this cohort have been reviewed by the trial safety committee and it has been deemed safe to proceed with the next dosage level. The trial is registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov) and has been provided with the identifier NCT04925050.

Latest news about Vectus Biosystems Limited

Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 23	CI
Vectus Biosystems Limited Announces the Change of its Registered Office and Principal Place of Business Address	Dec. 03	CI
Vectus Biosystems Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Vectus Biosystems Enrolls Patients, Begins Trials for Hypertension, Low Cardiovascular Risk Drug	23-06-15	MT
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-24	CI
Vectus Biosystems to Raise $2.3 Million From Share Placement	22-11-23	MT
Vectus Biosystems Halts Securities Trading Pending Fundraising Announcement	22-11-21	MT
Vectus Biosystems Limited Auditor Raises 'Going Concern' Doubt	22-09-28	CI
Vectus Biosystems Completes Phase Ia for Hypertension and Cardiovascular Drug	22-09-13	MT
Vectus Biosystems Limited Announces Completion of Phase Ia for VB0004	22-09-13	CI
Vectus Biosystems Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-31	CI
Vectus Biosystems Limited Announces Completion of Second M.A.D. Study for Vb0004	22-08-07	CI
Vectus Biosystems Limited Announces Completion of Final Single Ascending Dose Study and First Multiple Ascending Dose Study for VB0004	22-05-24	CI
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-25	CI
Vectus Biosystems Limited Announces Fourth of the Five Planned Cohorts in the Single Ascending Dose Segment of Its First-In-Human Tria	22-02-20	CI
Vectus Biosystems Limited Announces Third S.A.D. Group Reviewed by Trial Safety Review Committee	21-11-28	CI
Vectus Biosystems : Finishes Second SAD Segment of First-in-Human Hypertension Drug Trial	21-09-07	MT
Vectus Biosystems Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-08-31	CI
Vectus Biosystems : Completes Phase One Human Trial for Cardiovascular Disease	21-08-23	MT
Vectus Biosystems Limited Announces Successful Completion of First Group in Phase I Human Trial	21-08-22	CI
Vectus Biosystems : HREC Approves Vectus Biosystems' Phase One Human Trial for Hypertension Drug in Australia; Shares Surge 30%	21-06-16	MT
Approval Receives Approval from the Human Research Ethics Committee for Phase I Trial in Australia	21-06-16	CI
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2020	21-02-26	CI
Vectus Biosystems Limited Reports Earnings Results for the Full Year Ended June 30, 2020	20-08-31	CI
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2019	20-02-28	CI

Chart Vectus Biosystems Limited

Duration

Period

More charts

Company Profile

Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VECTUS BIOSYSTEMS LIMITED	-33.33%	7.11M
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research